Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in active psoriatic arthritis after inadequate response or intolerance to one prior anti-TNF agent
2021-000482-32Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Guselkumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 24. Started Jun 2021; status: active.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2021-000482-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000482-32.